Privi Speciality Chemicals Limited received a National Company Law Tribunal (NCLT) notice regarding the proposed scheme of amalgamation involving its subsidiaries. The Mumbai Bench directed that meetings for creditors of the transferor companies be dispensed with, while members of the transferee company will vote on October 27, 2026.

Scheme details

The scheme involves the amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with Privi Speciality Chemicals Limited. The first two entities act as Transferor Companies, while Privi Speciality Chemicals serves as the Transferee Company. The notice was issued pursuant to Section 230(5) of the Companies Act, 2013, following an order dated September 7, 2026.

Meeting requirements

The Tribunal dispensed with the requirement to hold separate meetings for:

• Members, secured, and unsecured creditors of Privi Fine Sciences Private Limited.
• Members and unsecured creditors of Privi Biotechnologies Private Limited.
• Secured and unsecured creditors of Privi Speciality Chemicals Limited.

A meeting of the equity shareholders of Privi Speciality Chemicals will be conducted through Online Audio Visual Mode (OAVM) on October 27, 2026, to consider and approve the scheme.

Procedural timeline

Stakeholders may submit representations regarding the scheme to the Tribunal within thirty days from the date of receiving this notice. A copy of any representation must simultaneously be sent to the registered office of the respective company. If no representation is received within the stipulated period, it will be presumed that there are no objections to the proposed amalgamation.

Privi Speciality Chemicals Ltd reported a reduction in institutional holding as SBI Mutual Fund disposed of 18,400 shares on September 24, 2026. The transaction lowered the mutual fund's aggregate stake across its various schemes to 7.3434% of the company's paid-up share capital.

Disclosure Details

The disposal was executed via market sale and disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Prior to this transaction, SBI Mutual Fund held 28,86,944 shares, representing 7.3905% of the equity. The sale reduced the absolute number of shares held by the fund by a marginal amount relative to its total position.

Shareholding Structure

The company's total equity share capital remained unchanged at ₹39,06,27,060, comprising 39,06,27,060 equity shares with a face value of ₹10 each. The disclosure confirms that the reduction pertains solely to shares carrying voting rights, with no encumbrances, warrants, or convertible securities involved in the transaction.

SBI Funds Management Limited, acting through its Chief Compliance Officer Vinaya Datar, submitted the filing to both BSE Limited and the National Stock Exchange of India Limited. The transaction date was recorded as September 24, 2026, with the formal intimation dated September 25, 2026.